{"entity":{"id":"nct03960840","kind":"trial","name":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","aka":[],"tldr":"A phase 1/2 trial of Ibrutinib in diffuse large b-cell lymphoma, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL is a phase 1/2 interventional study registered as NCT03960840 by Novartis Pharmaceuticals, with 217 participants enrolled, started 2019-06-26 and due to reach its primary completion in 2027-06-30. Interventions recorded: Rapcabtagene autoleucel single agent, Ibrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03960840","url":"https://clinicaltrials.gov/study/NCT03960840"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["ibrutinib"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03960840","phase":"1/2","setting":"Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","sponsor":"Novartis Pharmaceuticals","participation":[{"nct":"NCT03960840","source":"https://clinicaltrials.gov/study/NCT03960840","fetchedAt":"2026-10-07T16:53:11.482Z","studySha256":"ee2d4fceb4f523b0260152f13471184da0afd809b27357b047a6fdf3df29ee64","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-04","leadSponsor":"Novartis Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"100 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":217,"enrolmentType":"ACTUAL","siteCount":37,"recruitingSiteCount":0,"countries":["Australia","Austria","France","Germany","Italy","Japan","Spain","United States"]}],"started":"2019-06-26","startedType":"actual","enrolled":217,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03960840/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}